Aducanumab Gets Accelerated OK, Expert Says FDA Verdict Would Affect Japan Review Too

Amid the relentless controversy surrounding mixed PIII data, the US FDA handed accelerated approval to Biogen/Eisai’s Alzheimer’s disease (AD) drug Aduhelm (aducanumab) on June 7. A top Japanese expert says the agency’s verdict marks the “first step” towards a paradigm...read more